Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
How Patients With Cancer Can Best Care For Their Chemo Port
June 23rd 2022Care teams often implant a chemo port into patients with cancer to provide easy access for blood draws and to deliver treatments such as chemotherapy and antibiotics. Here, as part of its Heal at Home series, CURE® works with a nurse to provide a guide for patients to care for their port.
Educated Patient® Multiple Myeloma Summit Relapsed/Refractory Myeloma Presentation: March 12, 2022
April 3rd 2022Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.
Educated Patient® Multiple Myeloma Summit Newly Diagnosed Myeloma Presentation: March 12, 2022
April 2nd 2022Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.
'Give Yourself Grace’ Amidst the Potential Fear of Cancer Recurrence During Survivorship
March 31st 2022As a patient moves from treatment to survivorship, the fear of cancer recurrence may overshadow the ability for them to recognize how much they have endured, but support is available to hopefully lessen the burden.
Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer
March 25th 2022AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.
FDA Approves Second Keytruda Indication for Subset of Advanced Endometrial Cancer
March 21st 2022The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.
Multiple Myeloma is Being Diagnosed More Often in Younger Patients, But The Reasons Why Are Unclear
March 14th 2022As more and more people in their 20s and 30s begin to receive diagnoses of multiple myeloma, a type of blood cancer, one expert stresses that continued research to improve survival in this patient population is critical.